Head-to-head · Cost-Efficiency Index
AVArx vs Invyncible
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
AVArx
Shoppers who want a low advertised entry price and are comfortable getting exact dosing/cost only after a provider evaluation.
Visit AVArxInvyncible
Cost-first shoppers who want compounded GLP-1 combo programs (with B12/glycine) alongside brand Wegovy/Zepbound on one platform.
Visit InvyncibleThe verdict
AVArx and Invyncible tie on the Cost-Efficiency Index at 59/100, so neither wins outright on the numbers. For most shoppers we'd start with AVArx (ranked #267, a hair above #272) — Shoppers who want a low advertised entry price and are comfortable getting exact dosing/cost only after a provider evaluation. But Invyncible is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs AVArx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | AVArx | Invyncible |
|---|---|---|
| Cost-Efficiency Index | 59/100 | 59/100 |
| Semaglutide / mo | $199/mo (compounded) | $149/mo (0.45 mg dose, compounded with glycine + B12) |
| Tirzepatide / mo | $199/mo (compounded) | $180/mo (2.5 mg weekly, 4-week program, compounded) |
| Semaglutide / yr (modeled) | $2,388 | $1,788 |
| Tirzepatide / yr (modeled) | $2,388 | $2,160 |
| Coverage | All 50 states | 46 states plus DC |
| Oral / sublingual | No | Yes |
| Brand-name access | Compounded only | Yes |
| Rank here | #267 | #272 |
AVArx
59/100Where the value is
- Low advertised entry price ('GLP-1 care from $199')
- LegitScript verification seal displayed on the page
- Offers both semaglutide and tirzepatide evaluation
The tradeoffs
- The $199 headline price is not broken out by drug or dose -- real per-medication cost is undisclosed
- avarx.com (the intuitive domain) is actually a parked for-sale page, creating brand/domain confusion
Invyncible
59/100Where the value is
- Publishes real itemized dollar prices for eight separate combo programs plus two brand options directly on the site, no signup required, with the mg vial size named in every dose option
- Sells FDA-approved brand Wegovy ($1,750/mo) and Zepbound ($1,540/mo) alongside compounded options
- Names all six compounding pharmacies with street addresses and phone numbers and lets the patient choose which one fills the prescription
The tradeoffs
- Every listed price is shown as a discount off a much higher struck-through 'list' price, and the page invites further negotiation — reads as permanent anchor pricing
- The entry figure is the smallest vial: plain compounded semaglutide runs $192.50, $262.50 and $350 across its three vial sizes, and the FAQ confirms cost rises with dose
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.